Intercept's NASH hopeful gets preliminary thumbs down in FDA briefing docs
The FDA has once again raised safety concerns around the use of Intercept’s obeticholic acid in NASH, concluding in briefing documents ahead of an upcoming …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
